Mirabegron benefits men with OAB, erectile dysfunction
The selective β3-AR agonist mirabegron appears to confer benefits for both overactive bladder (OAB) symptoms and erectile dysfunction (ED) in some patients without compromising safety, as reported in a study.
The study included 20 patients aged 40–70 years who had concurrent OAB and mild-to-moderate ED. All of them had International Index of Erectile Function (IIEF) score 11–25, had International Prostate Symptom Score 8–20, and received mirabegron therapy for 12 weeks. These patients completed IIEF and OAB-q questionnaires on weeks 2, 4, 8, and 12. Adverse events (AEs) were assessed throughout the study.
Of the patients, seven were lost to follow-up and 13 (mean age 60.2 years, 38.4 percent White, mean body mass index 30.1 kg/m2) were included in the analysis.
At week 12, five patients (38.4 percent) achieved an increase of ≥4 points in the IIEF-5 score, the primary study endpoint. In the remaining eight patients (61.5 percent), there was neither a notable increase nor a clinically relevant reduction in IIEF-5 score.
Mirabegron also delivered significant improvements in intercourse satisfaction at week 8 relative to baseline (p=0.01). However, there were no beneficial effects on orgasmic function and sexual desire.
As expected, mirabegron reduced OAB symptoms assessed using the OAB-q short form (p=0.006) and OAB-q total health-related quality of life (HRQL) scores compared to baseline (p=0.03). Treatment had a no effect on residual bladder volumes.
None of the patients developed serious side effects during the study period.